| Moussa Tamer, MD | |
|
420 34th St, Bakersfield, CA 93301-2237 | |
| (661) 327-1792 | |
| Not Available |
| Full Name | Moussa Tamer |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 36 Years |
| Location | 420 34th St, Bakersfield, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124045778 | NPI | - | NPPES |
| 00G671420 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | G67142 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bakersfield Memorial Hospital | Bakersfield, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Coachella Valley Anesthesia A Professional Corporation | 5698131969 | 67 |
News Archive
An individual's ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that will help researchers better understand the biological bases for Alzheimer's disease and dementia in older populations.
A new hard coating with antibacterial properties that has been tested by researchers at the UCL Eastman Dental Institute has been shown to kill 99.9% of Escherichia coli bacteria when a white hospital light was shone on its surface to activate it.
› Verified 7 days ago
| Entity Name | Premier Anesthesia Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609880947 PECOS PAC ID: 2860472917 Enrollment ID: O20040825001711 |
News Archive
An individual's ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that will help researchers better understand the biological bases for Alzheimer's disease and dementia in older populations.
A new hard coating with antibacterial properties that has been tested by researchers at the UCL Eastman Dental Institute has been shown to kill 99.9% of Escherichia coli bacteria when a white hospital light was shone on its surface to activate it.
› Verified 7 days ago
| Entity Name | Coachella Valley Anesthesia A Professional Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013662048 PECOS PAC ID: 5698131969 Enrollment ID: O20230512000330 |
News Archive
An individual's ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that will help researchers better understand the biological bases for Alzheimer's disease and dementia in older populations.
A new hard coating with antibacterial properties that has been tested by researchers at the UCL Eastman Dental Institute has been shown to kill 99.9% of Escherichia coli bacteria when a white hospital light was shone on its surface to activate it.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Moussa Tamer, MD 3200 21st St Ste 301, Bakersfield, CA 93301-3108 Ph: (661) 334-1958 | Moussa Tamer, MD 420 34th St, Bakersfield, CA 93301-2237 Ph: (661) 327-1792 |
News Archive
An individual's ability to tolerate pain is influenced by their preconceptions and beliefs about the meaning of the pain, Italian researchers have shown.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
In a comprehensive analysis of samples from 107 aged human brains, researchers at the Allen Institute for Brain Science, UW Medicine and Kaiser Permanente Washington Health Research Institute have discovered details that will help researchers better understand the biological bases for Alzheimer's disease and dementia in older populations.
A new hard coating with antibacterial properties that has been tested by researchers at the UCL Eastman Dental Institute has been shown to kill 99.9% of Escherichia coli bacteria when a white hospital light was shone on its surface to activate it.
› Verified 7 days ago
Dr. Grant Wilson Peters, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1600 Truxtun Ave, Fifth Floor, Bakersfield, CA 93301 Phone: 661-393-3690 | |
Enrique Pardo, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 420 34th St, Bakersfield, CA 93301 Phone: 661-327-1792 | |
Dr. Janardhan Rao Grandhe, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5339 Truxtun Ave, Bakersfield, CA 93309 Phone: 661-327-9300 Fax: 661-327-9301 | |
Mr. John R Findley, MD Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: 9300 Stockdale Hwy, #200, Bakersfield, CA 93311 Phone: 661-663-3700 | |
Alicja Ogorkiewicz, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 500 Old River Rd, Suite 170, Bakersfield, CA 93311 Phone: 661-664-9600 Fax: 661-664-9699 | |
Clifford P Turk Iv, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 420 34th St, Bakersfield, CA 93301 Phone: 661-327-1792 | |
Dr. Philip Khoury, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3850 Riverlakes Dr Ste B, Bakersfield, CA 93312 Phone: 661-241-9330 |